ASP8232

DRUG3 trials

Sponsors

Astellas Pharma Europe B.V.

Conditions

Chronic Kidney DiseaseChronic Kidney Disease (CKD)Diabetes MellitusDiabetic Macular EdemaHealthy SubjectsPharmacodynamics of ASP8232Pharmacokinetics of ASP8232Type 2 Diabetes

Phase 1

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

CompletedNCT02218099

Astellas Pharma Europe B.V.Chronic Kidney Disease (CKD), Healthy Subjects, Pharmacodynamics of ASP8232 +2

Start: 2013-09-16End: 2014-09-09Updated: 2024-10-31

Phase 2

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

CompletedNCT02302079

Astellas Pharma Europe B.V.Diabetes Mellitus, Diabetic Macular Edema

Start: 2015-01-12End: 2016-08-12Updated: 2024-10-31

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

CompletedNCT02358096

Astellas Pharma Europe B.V.Chronic Kidney Disease, Type 2 Diabetes

Start: 2015-03-17End: 2017-03-15Updated: 2024-10-31

Related Papers

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema.

2019-08-0115 citations

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

2018-11-0637 citations